Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MMAT something to watch, up a buck after hours?
KNDI Kandi K23 1st Commercial
$IBIO established oncology drug pipeline with 3 new antibody programs.
$IDEX America’s First Manufacturer of Electric Tractors
With a range of 100% battery powered tractors, Solectrac is leading the transition to zero emission agriculture and utility operations with best-in-class technology for a safer, cleaner and healthier future.? https://ideanomics.com/
I am out but watching.
$IDEX Ideanomics Mobility is a turnkey solution that provides economic and operational confidence. With a synergistic ecosystem of products and services, we are helping commercial fleets navigate the barriers of electrification across vehicles, charging and energy. From vehicle procurement, to charging infrastructure, to energy management, we are demystifying fleet electrification, and delivering the simplicity and scalability our customers are looking for.? https://ideanomics.com/our-company/
WHOOPSIES! BWAAAAAAAAAAAA HAAAAAAAAAAAAAA!!
$MJNA Healthcare
Industry: Drug Manufacturers—Specialty & Generic
http://www.medicalmarijuanainc.com
$IDEX Electric Vehicles
Revisiting Chiasma
Dec. 02, 2020 6:48 AM ETChiasma, Inc. (CHMA)7 Comments11 Likes
Summary
Today, we revisit Chiasma for the first time in over a year.
This promising small-cap name recently posted some encouraging trial results and has seen a big recent insider purchase by its CEO.
We revisited the investment thesis on Chiasma in the paragraphs below.
I do much more than just articles at The Busted IPO Forum: Members get access to model portfolios, regular updates, a chat room, and more. Get started today »
Today, we take an in-depth look at a small-cap biotech concern for the first time since September 2019. The company continues to enjoy sparse but sanguine analyst coverage. More importantly, the equity saw the biggest insider buy in the shares in many, many years and also posted some recent encouraging trial results. We revisit the investment thesis in full in the paragraphs below.
Company Overview:
Chiasma Inc. (CHMA) is a Massachusetts based clinical-stage biopharmaceutical. The company focused on improving existing treatments for rare and serious chronic disease. Since we last revisited this name, the company's primary compound MYCAPSSA was approved in June of this year for the treatment of acromegaly. The drug started to hit the U.S. market in September.
Source: Company Presentation
MYCAPSSA is the only oral somatostatin analog and is a derivative of Chiasma's Transient Permeability Enhancer (TPE) technology platform, which was created to develop oral therapies as an alternative to injections.
Source: Company Presentation
The stock of Chiasma currently trades just over $4.00 a share and has an approximate market cap of $250 million. The shares came public in 2015 at $16.00 per share. Therefore, the stock is deep in 'Busted IPO' territory.
Recent Events:
On November 23rd, the CEO bought nearly half a million dollars of new shares. It was easily the biggest insider buy in the stock since the company came public in 2015. On November 18th, the company announced:
"Positive top-line data from its global Phase 3 MPOWERED non-inferiority clinical trial comparing Mycapssa to long-acting injectable somatostatin analogs (SSAs) for maintenance of biochemical response in patients with acromegaly."
Full data sets of this study will be presented at several medical conferences in the first half of 2021. The company plans to file for marketing approval for MYCAPSSA in Europe in mid-2021.
Balance Sheet & Analyst Commentary:
The company gets sparse but positive coverage from analyst firms. In mid-August, Jefferies initiated the shares with a Buy rating and $8 price target. Here is the commentary from the analyst at Jefferies.
"With an expected launch for Mycapssa, the first FDA-approved oral medication for acromegaly, in Q4, the analyst says the company is poised to capture a large portion of the market as patients move away from painful and burdensome injectable therapies. The analyst conservatively estimates that if ~50% of patients on injectables attempt the oral medication, the company could capture $300M+ in U.S. sales."
Source: Company Presentation
In addition, Piper Sandler reiterated its Buy rating and Street high $19 price target on CHMA on November 5th following third-quarter results. The analyst noted "that the company reported its first Mycapssa sales at $142K, and he sees strong demand for an effective oral therapy from acromegaly patients who currently receive painful monthly injections and experience break-through symptoms." H.C. Wainwright maintained its Buy rating and $10 price target on Chiasma the next day.
Thanks to a $75 million secondary raise in July as well as $25 million and $15 million fund infusions through the company's revenue interest finance agreement with Healthcare Royalty Partners which was triggered by the FDA approval and first commercial sale of MYCAPSSA, Chiasma ended the third quarter with just over $175 million of cash on the balance sheet. It posted a loss of $18.5 million in third quarter which should come down as MYCAPSSA ramps up in the coming quarters.
Verdict:
The stock is extremely cheap if the estimated peak sales of MYCAPSSA of $300 million are anywhere close to being in the ball park given they would be bigger than the company's current market cap. The compound also has many years of market exclusivity.
LMAO! Some funny twitter posts! BWAAAAAA HAAAAAAAAAAAAAA!
LOLOLOLLXXXXZXZXZXXLOLOLZZZZZZZZZZZZZZZZZZZZZZZZZZZZ!
Hope she enjoyed my "Liquidity" recommendation!
LOLOLXZXZZZZLOLOLXZXZZZZ
dump dump dump! CHUCKY!
Sir, can you provide a link on just how 30M more shares are coming? This leads us to believe 30M shares were just added, but looking at the filings, I do not see 30M shares added to the float anywhere.
Thank you,
LMFAO! This time next year cupcake...massive fail! LOLOLOLXZXZZZZZZLOLOLOZZZZZZZZZZZ
Once there was this guy who though he was really doing a good job of defending a penny stock scam...he would attack anyone who questioned the CEO...and all it did was make those people dig deeper and deeper into the CEO's past...dig deeper and deeper into the companies finances..each time they uncovered more and more dirt....but the guy just kept attacking....the pps was always falling due to all the dirt the posters kept finding....they would post it and get attacked again....they would find even more dirt...the price would drop even lower....all along the guy doing the attacking was actually destroying any chance for the stock to move up. He turned regular posters just asking questions into investigators ....they would have been long gone had they not been attacked. He himself motivated the posters to leave no stone un turned ..he was the one responsible for motivating people to expose everything about the company and ultimately the one responsible for the stock failing...and he never had a clue!
Have a nice day!
Wow Surg dropping into teens...something very wrong here...to bad!
SURG SCAM Q2 RECORD $8M LOSSES ....WHOOPSIES! lololxzxzzzlololzzzzz
Great work...thanks for confirming the MASSIVE DILUTION of over 10,000,000 shares...lolololzxzxlolzzzzz something is very wrong with SURG...wont end well with this rapid dilution! Outstanding Shares
113,154,744
07/01/2020Have A nice nice day!
Quote:Sorry, but the whole dilution BS was debunked last week.....Zero Dilution.....O/S still around 103M and float under 15M, those are the facts, no BS about it.
https://www.otcmarkets.com/stock/SURG/security
SURG CEO SEC SENT A CLEAR WARNING! WHOOOPSIES!
Dear Mr. Cox:
We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, not withstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
https://ir.surgeholdings.com/sec-filings/all-sec-filings/content/0000000000-19-013075/0000000000-19-013075.pdf
WHOOOOPSISES!
OUCH sorry about the huge losses again!...Dosnt look like the BIG BOYS are going to be selling for $5......LOLOLOLZZZXZXZXLOLOLOLZZZZZZZ
Virus video....interesting stats/predictions
$CVSI CV Sciences, Inc. Distribution Partnership With Harris Teeter
$TC The 1 analysts offering 12-month price forecasts for TuanChe Ltd have a median target of 42.22, with a high estimate of 42.22 and a low estimate of 42.22. The median estimate represents a +2,852.29% increase from the last price of 1.43. https://money.cnn.com/quote/forecast/forecast.html?symb=tc
Happy Holidays, everyone !
$BNGO Adoption of Its Saphyr® System by Clinical Cytogenetics Groups in Academia and Industry to Replace Traditional Methods for Clinical Testing https://www.globenewswire.com/news-release/2019/10/16/1930470/0/en/Bionano-Genomics-Announces-Adoption-of-Its-Saphyr-System-by-Clinical-Cytogenetics-Groups-in-Academia-and-Industry-to-Replace-Traditional-Methods-for-Clinical-Testing.html
Been in and tried 4-5 times to get a hold of you when I been in but i guess you don't see my comments for whatever reason there....
That is a very important rule to live by when trading the market! I've commented to you a few times when I was in your "space" but you never acknowledged me. I don't have private messaging. If you see tmbipa57 it's me.
Just never stray away from rule #1....never ever ever risk more than you can afford to lose without changing your life status.....not even for one day...because shit happens.
Unanimous adcom's like Amarin are nice risks though. Got back in on the 11th and surprise very positive FDA announcement Friday! That was fun but I agree with you that price action was disappointing. AGRX is next up.
Yes I agree it's safer to stay away from coin flips like Adcom's and the briefing docs release prior too...
Like up over 3% in AMRN right now.
Hey Burp, With the positive history, then watching the rigged adcomm meeting, it's the last time I'm long before adcomm and fda decisions. Some companies in the US do not want this approved due to loss of revenue and I'm amazed they were able to rig an adcomm decision. One rogue doctor allowed to run the entire show? Seen enough of this bio-crap. Going back to what has worked for me in the past, 1-2% steady gains.
$ALYI ALYI - Alternet Systems Q3 Financials Demonstrate Steady Progress
https://www.barchart.com/story/stocks/quotes/ALYI/overview/4011029/alyi-alternet-systems-q3-financials-demonstrate-steady-progress
Sorry , not today, but opinion not final.
Got it, you won't be disappointed, thx!
To understand you correctly, did you sell your 2k shares pre-market and cashed in your option at the low of Friday's trading? Or did you hold and just cashed in your option? Trying to understand the jargon.
"Thats why i sold $2.50 calls @ .60 to hedge...I covered at the open .05 and pocketed $1100.... now watch it run to $3 after the positive adcom vote....."
For as good as it is, I don't understand the Reuters article about the FDA staffers disapproval of it. Seemed more like a hit job by analyst/brokers trying to get their clients in cheap before Adcom. I missed this opportunity completely by holding, need 2.17 to break even. Will be more careful with these plays till I get my head around using options. I normally short theses kind of events.
CORV will get Adcom approval. Brinavess safety profile no worse than other PCV agents like procainamide or amio and being to able to rythym control 80 percent of patients within 12 mins is tremendous cost saving for everyone......
above post copied form twitter....
Just us chickens....
Who are you talking to?
Ok I'll talk to you here from now on.
$NIO Nio ES6 is a 317-mile electric SUV with a swappable, upgradable battery
https://www.cnet.com/roadshow/news/nio-es6-317-mile-electric-suv/
Spring Training Countdown Clock
http://www.springtrainingcountdown.com/#sthash.XgGolXkH.dpbs
Whose calling card is 777 shares? I’ve seen it before...
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |